Here's a number that should keep every behavioral health leader up at night: somewhere between 20 and 50 percent of psychotherapy patients drop out of treatment prematurely.
Let that sit for a moment.
The most comprehensive meta-analysis to date, Swift and Greenberg's landmark review of 669 studies representing nearly 84,000 clients, found a weighted average dropout rate of 19.7%. But that aggregate masks significant variability. When therapists were asked to judge dropout status themselves, their estimates climbed to around 40%. Earlier research by Wierzbicki and Pekarik in APA PsycNet, synthesizing 125 studies, found an average rate approaching 47%. The highest-risk window remains the first two to three sessions, with first-session dropout alone ranging from 20 to 57% across settings, a figure that has remained stubbornly stable across more than half a century of research.
This isn't a marginal problem. It's a structural failure in how we deliver mental health care, and it has real consequences.
Patients who drop out prematurely have worse therapeutic outcomes compared to completers. They're at an increased risk of hospitalization and are less likely to seek care again, ultimately creating a cycle of disengagement that can persist for months or years. For the clinician, premature termination carries its own toll: self-doubt, decreased confidence, and a sense of inadequacy that research suggests is more common than we acknowledge.
For practices, the financial impact is equally significant. Empty slots, lost downstream revenue, and higher acquisition costs per patient all compound when retention falls.
So, what drives dropout?
The research points to several interconnected factors. Weak therapeutic alliance is consistently identified as one of the strongest predictors. Financial constraints are consistently cited among the leading drivers of premature termination, with cost barriers appearing across diverse patient populations and practice settings. Logistical barriers, like transportation, scheduling, or childcare, create friction that makes consistent attendance unsustainable. And perhaps most importantly, many patients experience what researchers call "premature relief," or surface-level symptom improvement that masks unresolved underlying patterns.
A 2024 study by McGovern and colleagues added sharper detail to this picture, identifying specific early-warning indicators — including a single no-show in the first four sessions — as significant predictors of eventual dropout. The risk profile is identifiable. We just need the systems in place to act on it.
Here's where RTM enters the picture, not as a marketing tool, but as a clinical intervention.
Remote Therapeutic Monitoring creates a structured, continuous connection between the patient and the therapeutic process. Instead of asking patients to hold onto insights, cope with challenges, and maintain motivation in isolation for a week or two between sessions, RTM provides daily or near-daily touchpoints: a mood check-in, CBT exercise, or a quick self-assessment.
These may sound small, but the clinical implications are substantial.
First, engagement visibility. With RTM, clinicians can see whether a patient is engaging between sessions by completing exercises, logging data, or staying active in their treatment. If engagement drops, that's an early warning signal. A therapist can reach out proactively rather than waiting for a no-show.
Second, alliance reinforcement. The therapeutic relationship doesn't have to go dormant between sessions. When patients know their provider is reviewing their data and tracking their progress, the alliance extends beyond the consulting room. Research on measurement-based care (MBC) consistently demonstrates that sharing progress data with patients enhances engagement and therapeutic collaboration.
Third, early intervention at signs of risk. RTM data can surface concerning trends (like a sustained drop in mood, disrupted sleep, or decreased activity) that might not emerge until a crisis without continuous monitoring. This gives clinicians the opportunity to adjust treatment plans, escalate care, or simply reach out with a supportive message before problems compound.
Fourth, patient agency. There's growing evidence that patients who actively participate in tracking their own progress feel more invested in their treatment. The APA's review of MBC evidence found that MBC enhances patient involvement and strengthens patient-provider communication.
Now, I want to be direct about something: RTM is not a magic fix for dropout. The reasons patients leave therapy are complex, multifactorial, and deeply personal. No technology replaces a skilled clinician who knows how to build rapport, repair alliance ruptures, and adapt their approach to individual needs.
But technology can create scaffolding that makes it easier for patients to stay engaged between those critical face-to-face moments. And, when that scaffolding is also reimbursable (through CPT codes 98975 through 98981), practices have both the clinical rationale and the financial incentive to implement it.
We'll never eliminate premature dropout entirely. But we can stop treating it as an inevitability and start treating it as a problem we have tools to address.
In the next post, I'll walk through CPT code 98978, specifically designed for CBT monitoring, and explain why it represents a genuinely new chapter for mental health billing.
Question for you: What strategies have you found most effective at reducing dropout in your practice? I'd love to hear what's working.
#TherapyDropout #PatientRetention #TherapeuticAlliance #MentalHealth #RTM #BehavioralHealth #MeasurementBasedCare
